ARABIAN TIMES NEWS NETWORK
Geninova Biotech is a revolutionary company dedicated to transforming the landscape of diabetes treatment. Our mission is to provide groundbreaking solutions that not only manage but also reverse the condition of diabetic patients, empowering them to lead healthier and more fulfilling lives.
Chairman Mei Nan Tuan started Geninova Biotech with a vision to revolutionize healthcare outcomes in the UAE and the rest of the world. Geninova Biotech focuses on innovative biotechnological solutions to tackle pressing health issues, including diabetes and obesity, which are prevalent in the region. Under Chairman Tuan’s leadership, the company has made significant strides in developing advanced medical treatments and diagnostic tools, contributing to improved healthcare standards and patient outcomes.
Elizon M. Lazaro, the CEO of Geninova Biotech, oversees the company’s operations, ensuring that Geninova remains at the forefront of healthcare innovation. Lazaro fosters a culture of excellence, driving the company’s mission to deliver cutting-edge healthcare solutions.
Introducing Dibifree 180 : At the forefront of our innovative solutions is Dibifree 180, a revolutionary supplement-based treatment designed to completely reverse diabetes in just 180 days. Unlike traditional medicine-based treatments that can cause further complications, Dibifree 180 offers a safer alternative with two significant benefits:
- Complete Reversal of Diabetes: Dibifree 180 can improve and reverse the diabetic condition within 180 days, offering patients a new lease on life.
- Safe Weight Loss: Dibifree 180 promotes weight loss without the risk of major complications. Unlike medicine-grade weight loss regimes that can lead to severe issues such as pancreatitis, our supplement-based approach ensures a safer journey to a healthier weight and better overall health.
Based on our Phase 1 clinical trial conducted in Taiwan, Geninova Biotech has demonstrated a remarkable 90% efficacy in reversing diabetes. This groundbreaking achievement underscores our commitment to scientific excellence and our innovative approach to healthcare.
Integrated Digital Diabetes Management : The Dibifree 180 package includes an integrated digital diabetes management system to support patients throughout their journey to diabetes freedom. This system features a glucose watch for continuous glucose monitoring and Dr. Dibi, a personalized AI robot doctor. Dr. Dibi provides tailored assistance, offering online and offline support to help manage diabetes effectively. This comprehensive approach ensures that patients receive consistent care and guidance, enhancing their treatment experience and outcomes.
Other Revolutionary Breakthroughs: Virofree : In addition to Dibifree 180, Geninova Biotech is proud to introduce Virofree, another revolutionary breakthrough in our portfolio. Virofree is a herbal-based supplement designed to combat viral infections with unprecedented efficacy, particularly against the Omicron and Delta variants of the virus. This innovative solution has been detailed in a publication in Frontiers in Pharmacology, highlighting its ability to interrupt the effects of these variants and offering a significant advancement in antiviral therapy.
Strategic Collaborations with UAE Healthcare : Geninova Biotech is actively collaborating with the UAE healthcare sector to address the top four non-communicable diseases (NCDs) that account for 55% of the mortality rate in the UAE post-pandemic. By partnering with leading healthcare providers and institutions in the UAE, we aim to leverage our innovative treatments and expertise to significantly reduce the burden of these diseases and improve public health outcomes.
In a recent report to the World Health Organization (WHO), the UAE government highlighted its substantial investments in preventing NCDs. The report outlined the country’s efforts to avert a projected 32,000 deaths and a potential economic impact of USD 5 billion by 2034 due to these diseases. This commitment aligns with Geninova Biotech’s vision and reinforces the importance of our collaborative efforts in tackling these critical health challenges.
Publications and Patent : Geninova Biotech’s pioneering research has been featured in prominent journals, including Frontiers in Pharmacology. Our clinical trial for Dibifree 180 has been documented extensively, with publications detailing our methodology and results available for peer review. Our publication on Virofree in Frontiers in Pharmacology emphasizes its herbal-based formulation and its efficacy against the Omicron and Delta variants. Additionally, our innovative solutions have been recognized with several US patents, further validating our cutting-edge approach to biotechnology.
Seeking Investment and Strategic Partners : To further our R&D growth and expand our presence in the UAE, Geninova Biotech is now in partnership with Al Maktoum Investment Group to bring the revolutionary product to market and is actively seeking the right investments and strategic partnerships. We believe that collaboration with key stakeholders will accelerate our mission to deliver innovative healthcare solutions and improve patient outcomes. We are dedicated to fostering partnerships that align with our vision of transforming diabetes treatment and addressing the broader challenges of non-communicable diseases.
Participation in World Leaders Award and Business Forum : Geninova Biotech recently participated in the World Leaders Award and Business Forum in Dubai, a prestigious event where global leaders gather to discuss and forge business collaborations. During this event, Geninova Biotech announced a significant collaboration and partnership with the Al Maktoum Investment Group, headed by Group CEO Dr. Munir, representing the Office of HH Abdul Hakim Buti Al Maktoum. Furthermore, Mei Nan Tuan, the Chairman of Geninova Biotech, has been appointed by the office of His Highness to be the ambassador of the Al Maktoum Investment Group to Taiwan. This appointment aims to enrich business collaborations between the UAE and Taiwan and foster greater economic and technological exchanges.
Geninova Biotech is proud to lead the charge in diabetes treatment, combining cutting-edge science with a compassionate approach to patient care. Our dedication to innovation and patient well-being positions us as a leader in the biotech industry, committed to making diabetes a condition of the past and contributing to a healthier future for the UAE and beyond.